Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
ACTOPLUS MET vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
Initial: 15 mg pioglitazone/500 mg metformin twice daily or 30 mg pioglitazone/500 mg metformin once daily. Titrate gradually based on glycemic response. Maximum: 45 mg pioglitazone/2000 mg metformin per day in divided doses.
None Documented
None Documented
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Metformin: 6.2 hours (increased in renal impairment). Pioglitazone: 3-7 hours (parent), 16-24 hours (active metabolites), requiring once-daily dosing.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Metformin: 90% renal (unchanged), 10% fecal. Pioglitazone: 60-70% renal (metabolites), 20-30% fecal.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione